Novo Nordisk raids AstraZeneca for replacement to Jesper Brandgaard

15 October 2018

Jesper Brandgaard (pictured above) is to retire after 20 years with Danish pharma major Novo Nordisk (NOVN: VX), vacating the role of executive vice president, Biopharm and Legal Affairs.

Replacing him in the vice president of Biopharm role is Ludovic Helfgott, a Frenchman who was most recently global vice president of Anglo-Swedish drugmaker AstraZeneca’s (LSE: AZN) cardiovascular, metabolism and renal global franchise, supervising both assets in development and on the market.

Mr Helfgott, a Frenchman who has held operational leadership roles across Europe since joining AstraZeneca in 2005, will join Novo Nordisk in April 2019. Mr Brandgaard, who was also a chief financial officer during his two decades with the firm, will remain in his role until then.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK